Lipid Profile Improvement in Virologically Suppressed HIV-1-infected Patients Switched to Dolutegravir/Abacavir/Lamivudine: Data From the SCOLTA Project

Infection and Drug Resistance- New Zealand

doi 10.2147/idr.s203813

Full Text

Abstract

Available in

Date

Authors

Publisher

Informa UK Limited

Related search

Abacavir/Lamivudine Versus Tenofovir/Emtricitabine in Virologically Suppressed Patients Switching From Ritonavir-Boosted Protease Inhibitors to Raltegravir

AIDS Research and Human Retroviruses
VirologyInfectious DiseasesImmunology
2013English

No Difference in Effectiveness of Treatment Simplification to Boosted or Unboosted Atazanavir Plus Lamivudine in Virologically Suppressed in HIV-1-infected Patients

PLoS ONE
Multidisciplinary
2018English

Switch From Enfuvirtide to Raltegravir in Virologically Suppressed HIV-1 Infected Patients: Effects on Level of Residual Viremia and Quality of Life

Journal of Clinical Virology
VirologyInfectious Diseases
2009English

Dolutegravir/Abacavir/Lamivudine Versus Current ART in Virally Suppressed Patients (STRIIVING): A 48-Week, Randomized, Non-Inferiority, Open-Label, Phase IIIb Study

Antiviral Therapy
Infectious DiseasesPharmacology
2017English

Nevirapine-Raltegravir Combination, a NRTI and PI/r Sparing Regimen, as Maintenance Antiretroviral Therapy in Virologically Suppressed HIV-1-infected Patients

Antiviral Therapy
Infectious DiseasesPharmacology
2013English

Abacavir–Lamivudine Versus Tenofovir–Emtricitabine for Initial HIV-1 Therapy

New England Journal of Medicine
Medicine
2009English

96-Week Results of Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Plus Efavirenz, in Antiretroviral-Naive, HIV-1-infected Adults: ASSERT Study

Antiviral Therapy
Infectious DiseasesPharmacology
2013English

Pharmacokinetics and Acceptability of Once- Versus Twice-Daily Lamivudine and Abacavir in HIV Type-1-Infected Ugandan Children in the ARROW Trial

Antiviral Therapy
Infectious DiseasesPharmacology
2010English

Dual Therapy With Renally Adjusted Lamivudine and Dolutegravir: A Switch Strategy to Manage Comorbidity and Toxicity in Older, Suppressed Patients?

HIV Medicine
Health PolicyInfectious DiseasesPharmacology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy